Autosomal Recessive Hereditary Hypophosphatemic Rickets (ARHR)

Autosomal recessive hereditary hypophosphatemic rickets (ARHR) is a rare, inherited bone disease. In this condition, the kidneys lose too much phosphate in the urine. Phosphate is a mineral your bones need to grow strong and hard. When phosphate stays low in the blood for a long time, growing bones cannot mineralize well. This causes rickets in children (soft, bendable bones with leg bowing) and osteomalacia in adults (soft bones, bone pain, and fractures). “Autosomal recessive” means a child becomes affected when they inherit one non-working copy of a specific gene from each parent. Several different genes can cause ARHR. Some of these raise the hormone FGF23 (which makes the kidneys waste phosphate). Others reduce the kidney’s ability to take phosphate back from the urine. The end result is the same—chronic low phosphate, poor bone mineralization, and skeletal deformities. Merck Manuals+1

Autosomal recessive hereditary hypophosphatemic rickets is a rare genetic disease. Children inherit two faulty copies of a gene from their parents. Because of the gene change, the kidneys waste phosphate into the urine. Blood phosphate becomes low for a long time. Low phosphate weakens growth plates and bone mineral, causing rickets in children and osteomalacia (soft bone) in adults. Several genes can cause AR-HR. Common ones include DMP1, ENPP1, and FAM20C. These types are FGF23-mediated: the hormone FGF23 is inappropriately high, which reduces kidney phosphate reabsorption and vitamin D activation. AR-HR is different from HHRH (SLC34A3), which shows high calcitriol and hypercalciuria; AR-HR usually needs calcitriol plus phosphate, while HHRH needs phosphate alone. Early diagnosis and treatment improve growth and prevent deformity. PubMed+4PMC+4PMC+4

---

Other names

• ARHR (autosomal recessive hypophosphatemic rickets)

• ARHR1 (DMP1-related), ARHR2 (ENPP1-related), ARHR3 (FAM20C-related)

• Hereditary hypophosphatemic rickets (general term)

• Hereditary hypophosphatemic rickets with hypercalciuria (HHRH; SLC34A3-related) – a special recessive type with high urine calcium and low/normal FGF23, but still a phosphate-wasting rickets. Merck Manuals+2Genomics Education Programme+2

---

Types

1. ARHR1 (DMP1-related). DMP1 is a protein made by osteocytes (bone cells). When it is missing or not working, osteocytes signal abnormally and FGF23 rises, pushing the kidneys to waste phosphate. Children develop rickets, short stature, leg bowing, and dental problems. PMC+1

2. ARHR2 (ENPP1-related). ENPP1 normally makes pyrophosphate (PPi), which helps stop abnormal calcification. Without ENPP1, PPi is low and the body often raises FGF23—again causing phosphate loss. Some babies with ENPP1 changes have generalized arterial calcification of infancy (GACI) and later develop ARHR2; others present first with rickets. Frontiers+2PubMed+2

3. ARHR3 (FAM20C-related). FAM20C is a kinase that modifies many proteins in bone (including FGF23). Loss of FAM20C can cause Raine syndrome features (osteosclerosis, facial changes) and has been linked to hypophosphatemia and osteomalacia. ScienceDirect+1

4. HHRH (SLC34A3-related). This recessive type affects the kidney’s NPT2c phosphate transporter, so the kidney cannot reabsorb phosphate. It is FGF23-independent, often has high 1,25-dihydroxyvitamin D and hypercalciuria (lots of calcium in urine), and may cause kidney stones—yet the bone problem is still phosphate-wasting rickets. PMC+2Pediatric Endocrinology Journal+2

Note: All of these are recessive phosphate-wasting disorders. They differ mainly in which gene is affected and whether FGF23 is high (DMP1/ENPP1/FAM20C types) or normal/low (SLC34A3). Merck Manuals

---

Causes

1. Biallelic DMP1 loss-of-function variants (ARHR1) impair osteocyte signaling and raise FGF23. PMC

2. Biallelic ENPP1 variants (ARHR2) lower pyrophosphate and are linked to high FGF23 and phosphate loss. PubMed

3. Biallelic FAM20C variants (ARHR3) disturb protein phosphorylation in bone, affecting FGF23 processing. ScienceDirect

4. Biallelic SLC34A3 variants (HHRH) disable the NPT2c renal phosphate transporter. Pediatric Endocrinology Journal

5. Compound heterozygosity (two different bad variants in the same ARHR gene) causing loss of function. OUP Academic

6. Homozygosity due to parental consanguinity in an ARHR gene. sap.org.ar

7. Frameshift or nonsense variants that truncate DMP1/ENPP1/FAM20C/SLC34A3 proteins. PMC

8. Missense variants that change a key amino acid and disrupt protein function. Nature

9. Splice-site variants that prevent correct mRNA processing, yielding non-functional protein. PLOS

10. Large deletions/insertions removing essential coding regions. ScienceDirect

11. DMP1 pathway failure → excess FGF23 release from bone. PMC

12. ENPP1 pathway failure → low PPi and compensatory FGF23 elevation. Frontiers

13. FAM20C kinase failure → abnormal FGF23 processing and bone mineralization defects. ScienceDirect

14. NPT2c (SLC34A3) transporter failure → direct renal phosphate wasting (FGF23-independent). PMC

15. Founder variants within specific populations (reported in case series). PubMed

16. Gene interactions within phosphate homeostasis network (e.g., altered osteocyte–kidney signaling). OUP Academic

17. Developmental bone biology vulnerability (rapid growth increases phosphate needs; defects show earlier). OUP Academic

18. Modifier factors (individual differences that influence severity despite same gene). PubMed

19. Low PPi state (ENPP1) predisposing to ectopic calcification and secondary high FGF23. PubMed

20. Broad “hereditary hypophosphatemia” spectrum where ARHR subtypes cluster among known genetic causes. Genomics Education Programme

---

Common symptoms and signs

1. Bow-legs or knock-knees (genu varum/valgum), often noticed when a child starts walking. OUP Academic

2. Short stature or slow growth compared with peers. OUP Academic

3. Waddling gait and easy fatigue while walking. OUP Academic

4. Bone pain in legs, knees, or hips; worse with activity. Medscape Reference

5. Thickened wrists/ankles from growth-plate changes. Medscape Reference

6. Delayed walking or motor milestones. OUP Academic

7. Dental problems—delayed tooth eruption, weak enamel, or repeated dental abscesses. Merck Manuals

8. Frequent fractures or poor healing after minor trauma (more in adults with osteomalacia). Medscape Reference

9. Muscle weakness (especially proximal muscles in the thighs/hips). OUP Academic

10. Bone deformity progression despite vitamin D intake (vitamin D alone does not fix renal phosphate wasting). Medscape Reference

11. Head shape or craniofacial changes (can occur, especially with DMP1/FAM20C defects). Merck Manuals+1

12. Hearing issues (reported in some ARHR forms). Merck Manuals

13. Kidney stone or nephrocalcinosis risk (especially in SLC34A3/HHRH and sometimes from treatment). BioMed Central+1

14. Vascular calcification history in ENPP1 families (GACI survivors later showing rickets). ScienceDirect

15. General tiredness and limited activity due to bone pain and weakness. OUP Academic

---

Diagnostic tests

A) Physical examination

1. Growth measurements. Height, weight, and growth charts show slow growth and short stature for age. This helps track severity and response to therapy. OUP Academic

2. Leg alignment check. The doctor looks for bow-legs or knock-knees and measures angles at the knees and ankles. This documents rickets-related deformity. OUP Academic

3. Gait observation. Watching the child walk shows a waddling gait and stance changes typical of rickets with hip and thigh weakness. OUP Academic

B) Simple bedside/manual tests

4. Manual muscle testing. Gentle resistance testing grades hip and thigh strength and tracks improvement on treatment. OUP Academic

5. Joint range-of-motion checks. Limited knee/ankle motion and tight muscles around the joints are common with long-standing deformity. OUP Academic

6. Dental percussion and inspection. Tapping and examining teeth can uncover tenderness, abscesses, or enamel defects linked to hypophosphatemia. Merck Manuals

C) Laboratory and pathological tests

7. Serum phosphate (low). The key abnormal result—consistently low phosphate confirms a phosphate-wasting state. PMC

8. Alkaline phosphatase (high for age). A marker of active rickets/osteomalacia; usually elevated in growing children with rickets. PMC

9. Parathyroid hormone (PTH). Often normal or mildly up; helps rule out other causes of rickets (like vitamin D or calcium problems). PMC

10. 25-hydroxyvitamin D. Typically normal in ARHR; ensures we are not missing vitamin D deficiency. PMC

11. 1,25-dihydroxyvitamin D. May be inappropriately normal/low in FGF23-mediated forms (DMP1/ENPP1/FAM20C) but often high in HHRH (SLC34A3). This pattern helps sort the type. PMC

12. FGF23 (intact). Often elevated in DMP1/ENPP1/FAM20C forms; low/normal in SLC34A3/HHRH. Useful when available. Frontiers+1

13. Urine phosphate and TmP/GFR calculation. A low tubular phosphate reabsorption and low TmP/GFR show true renal phosphate wasting. OUP Academic

14. Genetic testing panel. Sequencing DMP1, ENPP1, FAM20C, SLC34A3 (and related genes) confirms the exact cause and guides family counseling. providers.genedx.com

D) Electrodiagnostic tests

15. Auditory brainstem response (ABR), when indicated. If hearing issues are suspected, ABR can document conductive or sensorineural changes reported in some hypophosphatemic rickets forms. (Not routine—used based on symptoms.) Merck Manuals

16. EMG/nerve conduction studies, selected cases. If muscle weakness looks out of proportion, these tests help rule out a neuromuscular disorder; rickets itself does not usually cause abnormal EMG. (Targeted use.) OUP Academic

E) Imaging tests

17. X-rays of wrists/knees/long bones. Classic rickets signs: widened, cupped, and frayed growth plates; osteopenia; bowing. These confirm active rickets and help grade severity. Medscape Reference

18. Skeletal survey (if needed). A fuller set of images looks for deformities, fractures, and skull changes (craniosynostosis in certain subtypes). Merck Manuals

19. Renal ultrasound. Screens for nephrocalcinosis or kidney stones—especially in SLC34A3/HHRH or after long-term high-dose phosphate therapy. BioMed Central

20. DXA (bone density) in older children/adults. Assesses bone mass and helps follow response to treatment; children need pediatric-aware interpretation. Medscape Reference

Non-pharmacological treatments

1. Education and care plan: Teach family about AR-HR, dosing times for phosphate and calcitriol, and blood/urine checks. Purpose: improve adherence and safety. Mechanism: informed self-management reduces under- and over-treatment and prevents complications like nephrocalcinosis. ec.bioscientifica.com

2. Nutrition consult: A dietitian sets a balanced plan with adequate protein and calories, normal calcium, and phosphate-rich whole foods while avoiding excess sodium. Purpose: support growth. Mechanism: ensures steady mineral supply and lowers stone risk by moderating salt. PMC

3. Sunlight hygiene (safe exposure): Short, safe sun exposure helps natural vitamin D, with sunscreen as appropriate. Purpose: maintain baseline 25(OH)D along with supplements if needed. Mechanism: UVB converts skin precursors to vitamin D. PMC

4. Physiotherapy – strength: Progressive hip and core strengthening. Purpose: improve gait and reduce falls. Mechanism: stronger muscles stabilize soft bone and joints. PMC

5. Physiotherapy – range of motion: Gentle stretching of hamstrings, calves, and hips. Purpose: keep joints mobile around deformed growth plates. Mechanism: reduces contractures from chronic malalignment. PMC

6. Gait training: Practice neutral alignment with cues and assistive devices if needed. Purpose: reduce stress on softened bones. Mechanism: redistributes load to safer vectors during ambulation. PMC

7. Orthotics/bracing: Guided growth braces during treatment windows. Purpose: slow or correct varus/valgus while bones heal. Mechanism: applies corrective forces across growth plates. PMC

8. Dental prevention program: Early referral, sealants, fluoride, and abscess management. Purpose: protect weak dentin/enamel. Mechanism: reduces bacterial invasion of hypomineralized teeth. PMC

9. Fall-prevention at home: Remove tripping hazards; good shoes. Purpose: reduce fractures. Mechanism: fewer high-impact events on soft bone. PMC

10. School accommodations: Rest breaks, lighter loads, PE modifications. Purpose: keep participation safe. Mechanism: matches activity to bone strength and endurance. PMC

11. Pain self-management: Heat packs, pacing, and gentle activity rather than bed rest. Purpose: control pain without overusing medicines. Mechanism: movement supports bone turnover and muscle function. ec.bioscientifica.com

12. Sleep optimization: Regular sleep supports growth hormone pulses. Purpose: growth and healing. Mechanism: deep sleep drives anabolic processes in children. PMC

13. Hydration plan: Encourage age-appropriate fluid intake. Purpose: kidney health when taking phosphate and vitamin D. Mechanism: adequate urine flow reduces stone risk. ec.bioscientifica.com

14. Weight management: Keep BMI in range. Purpose: less mechanical load on soft limbs. Mechanism: lowers varus/valgus progression. PMC

15. Psychosocial support: Counseling and support groups. Purpose: manage chronic pain, short stature concerns, and procedure anxiety. Mechanism: lowers stress and improves adherence. PMC

16. Regular monitoring schedule: Frequent labs (phosphate, calcium, ALP, PTH), urine Ca/Cr, and renal ultrasound. Purpose: safe titration. Mechanism: early detection of hyperparathyroidism or nephrocalcinosis. ec.bioscientifica.com

17. Orthopedic surveillance: Timed alignment films. Purpose: plan bracing vs. surgery. Mechanism: catches progression early. PMC

18. Dental emergency plan: Early antibiotics/drainage for abscess. Purpose: protect permanent teeth and growth. Mechanism: quick control of infection in vulnerable teeth. PMC

19. Genetic counseling: Explain autosomal recessive risk for future children. Purpose: family planning. Mechanism: clarifies 25% recurrence risk when both parents carry a variant. PMC

20. Care coordination: Endocrinology, nephrology, orthopedics, dentistry, physiotherapy work together. Purpose: whole-child care. Mechanism: reduces conflicting plans and gaps. PMC

---

Drug treatments

• Standard therapy for AR-HR (FGF23-mediated) is oral phosphate plus active vitamin D (calcitriol), carefully titrated and monitored. Burosumab is FDA-approved for X-linked hypophosphatemia (XLH) and TIO, not specifically for AR-HR; any use in AR-HR is off-label and should be specialist-led. The individual drug entries below cite FDA labels (accessdata.fda.gov) for what the medicine is and safety; indications may differ from AR-HR. Clinicians adapt dosing to the child and monitor calcium, phosphate, PTH, urine calcium, and kidneys. ec.bioscientifica.com+2FDA Access Data+2

1. Calcitriol (Rocaltrol®) – Class: active vitamin D3 analog. Typical pediatric doses are small (e.g., 0.25–0.5 mcg/day to start) and individualized. Time: daily in divided doses with phosphate. Purpose: raise intestinal calcium and phosphate absorption and suppress secondary hyperparathyroidism that can be triggered by phosphate therapy. Mechanism: 1,25-(OH)2D binds the vitamin D receptor to increase mineral absorption and modulate PTH. Side effects: hypercalcemia, hypercalciuria, nephrocalcinosis if over-treated; careful monitoring is essential. FDA Access Data+2FDA Access Data+2

2. Neutral phosphate salts (K-Phos® Neutral / Phospha 250 Neutral) – Class: oral phosphate replacement. Dosage is weight-based and split four times daily; pediatric dosing requires specialist oversight. Time: with meals and at bedtime. Purpose: directly replaces phosphate to normalize serum phosphate and heal rickets. Mechanism: provides absorbable phosphate to counter renal losses. Side effects: diarrhea, abdominal pain; overuse can cause hyperphosphatemia or secondary hyperparathyroidism. DailyMed+1

3. Potassium phosphates injection (hospital use) – Class: IV phosphate. Dose individualized in mmol; avoid mixing with calcium solutions. Time: only for acute/severe cases under monitoring. Purpose: corrects severe hypophosphatemia when oral intake is impossible. Risks: hyperkalemia, hypocalcemia; IV use is specialized. FDA Access Data

4. Doxercalciferol (Hectorol®) – Class: vitamin D2 analog that becomes active in vivo. Sometimes used when calcitriol is not tolerated; dosing and targets differ (primarily a CKD drug). Purpose/mechanism: increases active vitamin D activity to help control PTH in settings of secondary hyperparathyroidism; in AR-HR, any use is off-label and specialist-guided. Side effects: hypercalcemia, hyperphosphatemia; requires close labs. FDA Access Data+1

5. Paricalcitol (Zemplar®) – Class: vitamin D analog. Similar rationale as doxercalciferol for PTH control in specific contexts; mostly CKD-related indications. Risks include hypercalcemia and hyperphosphatemia; pediatric use in AR-HR is off-label. FDA Access Data+1

6. Calcifediol ER (Rayaldee®) – Class: 25-hydroxyvitamin D3. Used for CKD-related secondary hyperparathyroidism; in AR-HR, the priority is calcitriol, but calcifediol can optimize 25(OH)D when deficient per specialist judgment. Side effects: hypercalcemia; several drug interactions (e.g., cholestyramine, enzyme inducers). FDA Access Data+1

7. Hydrochlorothiazide (HCTZ / Microzide®) – Class: thiazide diuretic. Lowers urinary calcium. Purpose: if hypercalciuria or nephrocalcinosis develops during therapy, a thiazide may reduce calcium loss. Mechanism: increases distal tubular calcium reabsorption. Side effects: low potassium, high uric acid, glucose effects; monitor electrolytes. FDA Access Data

8. Potassium citrate (Urocit-K®) – Class: urinary alkalinizer/citrate. Purpose: kidney stone prevention when urine citrate is low (selected patients with nephrocalcinosis risk). Mechanism: citrate binds urinary calcium and reduces crystal formation. Side effects: GI upset; careful use with potassium-affecting drugs. FDA Access Data+1

9. Acetazolamide (Diamox®) – Class: carbonic anhydrase inhibitor. Sometimes considered to manipulate urinary chemistry in complex stone scenarios but can increase phosphate loss; any use is rare and specialist-only. Side effects: metabolic acidosis, paresthesias; avoid routine use. FDA Access Data+1

10. Somatropin (Norditropin®) – Class: growth hormone. In children with proven GH deficiency or severe growth failure despite optimized mineral therapy, GH may be considered by endocrinology; not a primary AR-HR drug. Side effects: edema, intracranial hypertension risk; careful selection and monitoring. FDA Access Data+1

11. Cinacalcet (Sensipar®) – Class: calcimimetic. Rarely, if stubborn secondary hyperparathyroidism persists during high-dose phosphate therapy, specialists may consider calcimimetic use off-label to control PTH. Risks: hypocalcemia, GI symptoms. FDA Access Data+2FDA Access Data+2

12. Sevelamer (Renagel®) – Class: phosphate binder. Not used to treat AR-HR itself (it lowers phosphate). It may be used briefly if hyperphosphatemia occurs in specific scenarios, but this is uncommon in FGF23-mediated disease receiving replacement. Side effects: GI upset; avoid if bowel obstruction. FDA Access Data+2FDA Access Data+2

13. Cholecalciferol (vitamin D3, OTC) – Class: nutritional vitamin D. Purpose: keep 25(OH)D sufficient while calcitriol does the active work. Mechanism: maintains substrate for vitamin D system; dosing per age and level. Side effects: hypercalcemia if very high doses. (Labeling is OTC; practice guidance supports sufficiency checks.) PMC

14. Analgesics (acetaminophen/ibuprofen) – Class: pain relievers for symptomatic control. Purpose: reduce bone pain while definitive therapy heals rickets. Mechanism: central (acetaminophen) or anti-inflammatory (ibuprofen). Side effects: liver (acetaminophen) or GI/renal (NSAIDs). Use sparingly under clinician advice. PMC

15. Burosumab (Crysvita®) – Class: anti-FGF23 monoclonal antibody. FDA-approved for XLH and TIO, not specifically for AR-HR; some centers may consider off-label in selected genotypes, but data are limited. Dosing is by weight; oral phosphate and active vitamin D should be stopped before starting per label. Risks: injection reactions, hypersensitivity. Decision requires expert review. FDA Access Data+2FDA Access Data+2

16. Magnesium repletion (if low) – Class: mineral supplement. Purpose: corrects hypomagnesemia that can worsen PTH resistance and bone health. Mechanism: supports PTH/vitamin D axis. Side effects: diarrhea with high doses. PMC

17. Calcium supplements (short-term, targeted) – Class: mineral. Purpose: only if dietary calcium is insufficient or transient hypocalcemia appears; avoid excess. Mechanism: supports mineralization with calcitriol. Risks: hypercalciuria; monitor closely. PMC

18. Active vitamin D analog rotation (e.g., switch between calcitriol and others) – Strategy to improve tolerance when labs fluctuate; strictly specialist-led. FDA Access Data+1

19. Phosphate dose splitting – Although not a “drug,” precise splitting (3–5 times/day) improves tolerance and minimizes PTH spikes; combined here as a medication-use practice. ec.bioscientifica.com

20. Drug interaction management – Avoid combining oral phosphate with burosumab (per label), and check interactions for vitamin D analogs (e.g., cholestyramine reduces calcifediol absorption). FDA Access Data+1

---

Dietary molecular supplements

1. Vitamin D3 (cholecalciferol): Keep 25(OH)D in the sufficient range while active vitamin D is prescribed. Typical maintenance: 600–1,000 IU/day in children (more if deficient, per labs). Function: prevents overlay of nutritional deficiency on genetic rickets. Mechanism: supplies substrate for 25-OH vitamin D. Use only with clinician monitoring to avoid hypercalcemia. PMC

2. Calcium (diet first; supplement if needed): If dietary intake is low for age, a small calcium supplement may be added. Dosage: individualized (often 200–500 mg/day extra when required). Function: supports mineralization with calcitriol. Mechanism: provides ionized calcium for bone matrix. Monitor urine calcium and kidneys. PMC

3. Magnesium: Correct low magnesium if present (e.g., 5–10 mg/kg/day elemental magnesium in divided doses, per clinician). Function: cofactor for PTH secretion and vitamin D metabolism. Mechanism: stabilizes ATP reactions and parathyroid function. GI upset is common. PMC

4. Phosphate-rich foods: Lean meats, dairy, legumes, nuts, and whole grains. Dose: food-based, not pills, to complement prescriptions. Function: provides background phosphate. Mechanism: improves total phosphate balance. Avoid ultra-processed foods with phosphate additives unless advised, as they can disrupt calcium-phosphate balance. PMC

5. Protein adequacy: Ensure age-appropriate protein intake. Function: supplies amino acids for collagen matrix. Mechanism: collagen is the scaffold for mineral deposition. Work with a dietitian if appetite is low. PMC

6. Fluoride toothpaste and professional fluoride: For tooth strength. Mechanism: improves enamel resistance in hypomineralized teeth. Follow pediatric dental guidance; do not exceed dosing. PMC

7. Omega-3 fatty acids (food-based): Fish or fortified foods may help general inflammation and pain perception. Function: supportive wellness; not disease-modifying. Mechanism: alters eicosanoids. Use food-first approach. PMC

8. Citrate-rich hydration: Lemon/lime fluids (not sweetened) add citrate. Function: in select patients with low citrate, may support kidney stone prevention alongside medical therapy. Mechanism: citrate complexes urinary calcium. Use under clinician guidance. FDA Access Data

9. Iron sufficiency: Treat iron deficiency if present. Function: growth and energy. Mechanism: supports erythropoiesis and child development; unrelated to phosphate but important for overall health. Dose per labs. PMC

10. Iodized salt (moderate use): Ensures iodine sufficiency for thyroid and growth while avoiding high sodium, which can increase calciuria. Mechanism: supports growth; avoid excessive salt because it raises urinary calcium. PMC

---

Immunity booster / regenerative / stem-cell drugs

There are no FDA-approved stem-cell or “immunity booster” drugs for AR-HR. Some bone-active drugs approved for other diseases are sometimes discussed, but they are not approved for AR-HR and carry real risks. Below are six items to clarify evidence and safety:

1. Teriparatide / Abaloparatide (bone anabolic): FDA-approved for osteoporosis in adults, not for children or AR-HR; safety in growing skeletons is a concern. Any use would be off-label and generally avoided in pediatrics. (General caution based on endocrine guidance.) PMC

2. Romosozumab (Evenity®): Anabolic/antiresorptive for postmenopausal osteoporosis with cardiovascular warnings; not for AR-HR or children. Off-label use is inappropriate. OUP Academic

3. Denosumab (Prolia®): Antiresorptive for osteoporosis; may worsen mineralization in rickets contexts; not indicated for AR-HR. Off-label use requires extreme caution. OUP Academic

4. Somatropin (Norditropin®): Growth hormone is not an immunity booster; it is only considered for confirmed GH deficiency or special growth indications, not to “regenerate” bone in AR-HR. FDA Access Data

5. Calcitriol and vitamin D analogs: These are standard metabolic therapies, not stem cells; they help correct mineral metabolism. Use per label precautions. FDA Access Data

6. Burosumab (Crysvita®): Anti-FGF23 biologic approved for XLH/TIO, not AR-HR. Any use in AR-HR is off-label, with limited data; requires expert risk-benefit review. FDA Access Data

---

Surgeries

1. Guided growth (temporary hemiepiphysiodesis): A small plate and screws on one side of the growth plate to correct varus/valgus gradually as the child grows. Why: align legs while medical therapy strengthens bone. PMC

2. Corrective osteotomy: Surgical bone cuts to realign severe deformity in adolescents or adults when growth is near complete or bracing fails. Why: restore axis, improve gait, and reduce pain. PMC

3. Prophylactic fixation of stress fractures (selected cases): Internal fixation of nonhealing pseudofractures. Why: reduce pain and speed function recovery during mineral correction. ec.bioscientifica.com

4. Dental surgeries: Drainage of abscesses, root canal, or extraction when teeth are severely affected. Why: remove infection source and protect permanent dentition. PMC

5. Orthopedic hardware removal/adjustment: After guided growth or osteotomy heals, hardware may be removed. Why: prevent irritation and allow normal growth. PMC

---

Preventions

1. Early diagnosis and treatment to protect growth plates. PMC

2. Regular lab and ultrasound monitoring to catch complications early. ec.bioscientifica.com

3. Adherence to divided phosphate and calcitriol dosing. ec.bioscientifica.com

4. Keep 25(OH)D sufficient with supervised vitamin D. PMC

5. Safe physical activity to build muscle without impact overload. PMC

6. Orthopedic follow-up for progressive deformity. PMC

7. Dental preventive care every 3–6 months. PMC

8. Hydration and moderate sodium to protect kidneys. ec.bioscientifica.com

9. Avoid unsupervised supplements that can upset calcium-phosphate balance. PMC

10. Family genetic counseling for future pregnancies. PMC

---

When to see doctors (red flags)

See your child’s specialist urgently for: new or worsening leg bowing or pain, inability to walk or sudden limp, severe bone pain at rest, fever with dental swelling (possible abscess), decreased urine or flank pain (possible stones), vomiting/constipation or confusion (could signal high calcium), or if you miss doses and cannot restart safely. Regular visits should include labs, urine checks, growth review, and kidney ultrasound per plan. PMC+1

---

What to eat and what to avoid

1. Eat: balanced meals with lean protein, legumes, nuts, whole grains, fruits, and vegetables. Purpose: growth and mineral support. PMC

2. Eat: normal-calcium foods (milk/yogurt/cheese in age-appropriate amounts) unless told otherwise. PMC

3. Eat: foods naturally containing phosphate (eggs, dairy, legumes) to complement prescriptions. PMC

4. Drink: enough water daily; include natural citrus if advised for citrate. FDA Access Data

5. Avoid: very high sodium foods (packaged snacks, instant noodles) that raise urinary calcium. PMC

6. Avoid: unregulated “bone boosters” or mega-vitamin D without labs. PMC

7. Avoid: excessive cola/soft drinks; some contain phosphoric acid and sugar but do not correct phosphate balance safely. PMC

8. Avoid: very high vitamin A or retinoids without medical advice (can affect bone). PMC

9. Limit: high-oxalate foods only if stones occur and your clinician advises. PMC

10. Time doses with meals as instructed; keep a schedule for divided phosphate. DailyMed

---

FAQs

1. Is AR-HR curable? No. It is lifelong. But treatment can normalize growth and function and prevent deformity. ec.bioscientifica.com

2. How is AR-HR different from HHRH? HHRH (SLC34A3) has high calcitriol and hypercalciuria and often needs phosphate alone; AR-HR is FGF23-mediated and needs calcitriol plus phosphate. PubMed+1

3. Why divide phosphate doses? Small, frequent doses are better tolerated and lessen PTH spikes. ec.bioscientifica.com

4. Do all children need surgery? No. Many improve with medical therapy and bracing; surgery is for severe or persistent deformity. PMC

5. Can we use burosumab? It is FDA-approved for XLH/TIO, not specifically AR-HR. Off-label use is a specialist decision based on genotype and evidence. FDA Access Data

6. Will teeth always have problems? Early dental care reduces abscess risk; mineral therapy helps, but enamel/dentin may still be fragile. PMC

7. How often are labs needed? Often every 1–3 months at the start, then spaced out; your team will set a schedule. Labs track phosphate, calcium, ALP, PTH, and urine calcium. ec.bioscientifica.com

8. What are the dangers of overtreatment? High calcium in blood or urine, nephrocalcinosis, and suppressed growth if PTH is driven too low. ec.bioscientifica.com

9. Is vitamin D alone enough? No. In AR-HR you need phosphate replacement and active vitamin D together, unless your subtype dictates otherwise. ec.bioscientifica.com

10. Can adults be diagnosed? Yes. Adults may present with bone pain, pseudofractures, and short stature; genetic testing confirms. ec.bioscientifica.com

11. Does diet replace medicine? No. Diet supports health but does not correct renal phosphate wasting. PMC

12. Are thiazides safe? They can help hypercalciuria in selected patients but need electrolyte monitoring. FDA Access Data

13. Will children catch up in height? Many improve with early, consistent therapy, but final height depends on timing and severity. ec.bioscientifica.com

14. Do we stop therapy after puberty? Not always. Adults may need ongoing care for osteomalacia and pain; plans are individualized. ec.bioscientifica.com

15. Who should lead care? Pediatric endocrinology (or metabolic bone clinic) with nephrology, orthopedics, and dentistry.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 07, 2025.